Hastings Randolph H, Montgrain Philippe R, Quintana Rick A, Chobrutskiy Boris, Davani Ashkhan, Miyanohara Atsushi, Mahooti Sepi
Anesthesiology Service, VA Medical Center (125), VA San Diego Healthcare System, 3350 La Jolla Village Dr., San Diego, CA, 92161, USA.
Research Service, VA San Diego Healthcare System, San Diego, USA.
J Cancer Res Clin Oncol. 2017 Aug;143(8):1395-1407. doi: 10.1007/s00432-017-2396-4. Epub 2017 Mar 25.
Expression of the carboxyl PTHrP region of parathyroid hormone-related protein (PTHrP) is a positive prognostic indicator in women with lung cancer, but amino PTHrP is a negative indicator in other lung cancer patients. This project investigated whether PTHrP could be expressed as predominantly amino PTHrP or carboxyl PTHrP in individual lung carcinomas. It also assessed domain-specific effects on cancer progression and patient survival.
PTHrP immunoreactivities were analyzed versus survival in a human lung cancer tissue microarray (TMA). Growth was compared in athymic mice for isogenic lung carcinoma xenografts differing in expression of amino and carboxyl PTHrP domains.
In the TMA, 33 of 99 patient tumors expressed only one PTHrP domain, while 54 expressed both. By Cox regression, the hazard ratio for cancer-specific mortality (95% confidence interval) was 2.6 (1.28-5.44) for amino PTHrP (P = 0.008) and 0.6 (0-2.58) for carboxyl PTHrP (P = 0.092). Xenografts of H358 lung adenocarcinoma cells that overexpressed amino PTHrP grew twice as fast as isogenic low PTHrP tumors in athymic mice, but growth of tumors expressing amino plus carboxyl PTHrP was not significantly different than growth of the control tumors. In summary, the presence of amino PTHrP signifies worse prognosis in lung cancer patients. In mouse xenografts, this effect was abrogated if carboxyl PTHrP was also present.
Amino PTHrP and carboxyl PTHrP can vary independently in different lung carcinomas. Carboxyl PTHrP may temper the stimulatory effect of amino PTHrP on cancer progression.
甲状旁腺激素相关蛋白(PTHrP)羧基端区域的表达是肺癌女性患者的一个阳性预后指标,但氨基端PTHrP在其他肺癌患者中是一个阴性指标。本项目研究了在个体肺癌中PTHrP是否主要以氨基端PTHrP或羧基端PTHrP的形式表达。它还评估了特定结构域对癌症进展和患者生存的影响。
在人肺癌组织微阵列(TMA)中分析PTHrP免疫反应性与生存率的关系。比较了无胸腺小鼠中表达氨基端和羧基端PTHrP结构域不同的同基因肺癌异种移植瘤的生长情况。
在TMA中,99例患者肿瘤中有33例仅表达一个PTHrP结构域,而54例同时表达两个结构域。通过Cox回归分析,氨基端PTHrP导致癌症特异性死亡的风险比(95%置信区间)为2.6(1.28 - 5.44)(P = 0.008),羧基端PTHrP为0.6(0 - 2.58)(P = 0.092)。在无胸腺小鼠中,过表达氨基端PTHrP的H358肺腺癌细胞异种移植瘤的生长速度是同基因低PTHrP肿瘤的两倍,但同时表达氨基端和羧基端PTHrP的肿瘤生长与对照肿瘤相比无显著差异。总之,氨基端PTHrP的存在表明肺癌患者预后较差。在小鼠异种移植瘤中,如果同时存在羧基端PTHrP,这种影响会被消除。
在不同的肺癌中,氨基端PTHrP和羧基端PTHrP可以独立变化。羧基端PTHrP可能会缓和氨基端PTHrP对癌症进展的刺激作用。